Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22674611 | 0.85 | ARG1 (0.34) | ARG1ARG2GGPS1FDPSAGTR1 | |
| SCHEMBL23695719 | 0.82 | SIGMAR1 (0.42) | ARG1ARG2GGPS1FDPSAGTR1 | |
| SCHEMBL18797998 | 0.82 | — | — | |
| SCHEMBL23983093 | 0.80 | ARG1 (0.34) | ARG1ARG2GGPS1FDPSAGTR1 | |
| SCHEMBL22299487 | 0.79 | PRMT3 (0.42) | SIGMAR1 | |
| SCHEMBL12156851 | 0.79 | ARG1 (0.36) | ARG1ARG2GGPS1FDPSAGTR1 | |
| SCHEMBL14016289 | 0.77 | — | — | |
| SCHEMBL22109500 | 0.76 | GGPS1 (0.39) | GGPS1FDPSAGTR1OPRM1PDE3A | |
| SCHEMBL21076271 | 0.76 | — | — | |
| SCHEMBL16256528 | 0.76 | DRD2 (0.36) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | ARG1 2260/4885ARG2 1379/4885GGPS1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.